March 20, 2018 @ 11:00 am – 12:15 pm
  • Manfred Schmidt
    Vector Persistence and Safety Considerations in Gene Therapy
  • Axel Schambach
    State-of-the-art assay systems to assess genotoxicity of integrating vectors
  • Speakers selected from abstracts: 1 x 15 min
    • Myriam Lemmens
      Development of an in vitro human cell transformation assay in order to evaluate the carcinogenicity of CRISPR/Cas9 based genome editing